Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells

Journal of Clinical Oncology

Volumn 23, Issue 35, 2005, Pages 9008-9021

  Van Baren, Nicolas ^a   Bonnet, Marie Claude ^b   Dréno, Brigitte ^b   Khammari, Amir ^b   Dorval, Thierry ^b   Piperno Neumann, Sophie ^b   Liénard, Danielle ^b   Speiser, Daniel ^b   Marchand, Marie ^b   Brichard, Vincent G ^b   Escudier, Bernard ^b   Négrier, Sylvie ^b   Dietrich, Pierre Yves ^b   Maraninchi, Dominique ^b   Osanto, Susanne ^b   Meyer, Ralf G ^b   Ritter, Gerd ^b   Moingeon, Philippe ^b   Tartaglia, Jim ^b   Van Der Bruggen, Pierre ^b   Coulie, Pierre G ^b   Boon, Thierry ^b   more..

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALVAC MINIMAGE VACCINE; C REACTIVE PROTEIN; HLA A1 ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; RECOMBINANT VACCINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VIRUS VACCINE; ALVAC VACCINE; CANCER VACCINE; MAGEA1 PROTEIN, HUMAN; MAGEA3 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR PROTEIN;

ABDOMINAL PAIN; ADULT; AGED; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANXIETY; ARTHRALGIA; ARTICLE; ASTHENIA; CANARYPOX VIRUS; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; DRUG MECHANISM; DYSPNEA; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNE RESPONSE; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE INFLAMMATION; INJECTION SITE NECROSIS; INJECTION SITE PAIN; MALE; MELANOMA; MULTICENTER STUDY; MYALGIA; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; T LYMPHOCYTE; TACHYCARDIA; TREATMENT RESPONSE; VACCINATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CANARYPOX VIRUS; CANCER VACCINES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; VIRAL VACCINES;

EID: 28844471692     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.08.375     Document Type: Article

References (40)

1. Van den Eynde BJ, van der Bruggen P: T cell defined tumor antigens. Curr Opin Immunol 9:684-693, 1997
2. Boon T, Van den Eynde BJ: Shared tumor-specific antigens, in Rosenberg SA (ed): Principles and Practice of the Biologic Therapy of Cancer. Bethesda, MD, Lippincott Williams & Wilkins, 2001, pp 493-504
3. Marchand M, van Baren N, Weynants P, et al: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80:219-230, 1999
4. Marchand M, Punt CJ, Aamdal S, et al: Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: A clinical report. Eur J Cancer 39:70-77, 2003
5. Thurner B, Haendle I, Röder C, et al: Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669-1678, 1999
6. Coulie PG, Karanikas V, Colau D, et al: A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A 98:10290-10295, 2001
7. Lonchay C, van der Bruggen P, Connerotte T, et al: Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci U S A 101:14631-14638, 2004 (suppl 2)
8. Bonnet MC, Tartaglia J, Verdier F, et al: Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol Lett 74:11-25, 2000
9. Schlom J, Panicali D: Recombinant poxvirus vaccines, in Rosenberg SA (ed): Principles and Practice of the Biologic Therapy of Cancer. Bethesda, MD, Lippincott Williams & Wilkins, 2001, pp 686-694
10. de Bruyn G, Rossini AJ, Chiu Y-L, et al: Safety profile of recombinant canarypox HIV vaccines. Vaccine 22:704-713, 2004
11. Hörig H, Lee DS, Conkright W, et al: Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 49: 504-514, 2000
12. Menon AG, Kuppen PJ, Van Der Burg SH, et al: Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients. Cancer Gene Ther 10:509-517, 2003
13. Marshall JL, Hawkins MJ, Tsang KY, et al: Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 17:332-337, 1999
14. Ullenhag GJ, Frodin J-E, Mosolits S, et al: Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony-stimulating factor induced a tumor-specific cellular immune response. Clin Cancer Res 9:2447-2456, 2003
15. van der Burg SH, Menon AG, Redeker A, et al: Induction of p53-specific Immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin Cancer Res 8:1019-1027, 2002
16. Chaux P, Luiten R, Demotte N, et al: Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol 163:2928-2936, 1999
17. Traversari C, van der Bruggen P, Luescher IF, et al: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176:1453-1457, 1992
18. Gaugler B, Van den Eynde B, van der Bruggen P, et al: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921-930, 1994
19. Perkus ME, Limbach K, Paoletti E: Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol 63:3829-3836, 1989
20. National Cancer Institute of Canada Clinical Trials Group: Expanded Common Toxicity Criteria. Kingston, Ontario, Canada, National Cancer Institute of Canada Clinical Trials Group, 1994, pp 1-35
21. WHO: Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization Offset, Publication No. 48, 1979
22. Miller AB, Hogestraeten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
23. Karanikas V, Lurquin C, Colau D, et al: Monoclonal Anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol 171:4898-4904, 2003
24. Herr W, Linn B, Leister N, et al: The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. J Immunol Methods 203:141-152, 1997
25. Britten CM, Meyer RG, Kreer T, et al: The use of HLA-A*0201- transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays. J Immunol Methods 259:95-110, 2002
26. Stockert E, Jager E, Chen YT, et al: A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187:1349-1354, 1998
27. Luiten RM, Demotte N, Tine J, et al: A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules. Tissue Antigens 56:77-81, 2000
28. Schultz ES, Zhang Y, Knowles R, et al: A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes. Tissue Antigens 57:103-109, 2001
29. Franchini G, Gurunathan S, Baglyos L, et al: Poxvirus-based vaccine candidates for HIV: Two decades of experience with special emphasis on canarypox vectors. Expert Rev Vaccines 3:875-888, 2004
30. Lurquin C, Lethe B, De Plaen E, et al: Contrasting frequencies of antitumor and antivaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 201:249-257, 2005
31. Antonia S, Mule JJ, Weber JS: Current developments of immunotherapy in the clinic. Curr Opin Immunol 16:130-136, 2004
32. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: Moving beyond current vaccines. Nat Med 10:909-915, 2004
33. Godelaine D, Carrasco J, Lucas S, et al: Polyclonal cytolytic T lymphocyte responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 171:4893-4897, 2003
34. Germeau C, Ma W, Schiavetti F, et al: High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 201:241-248, 2005
35. Topalian SL, Horn SS, Kawakami Y, et al: Recognition of shared melanoma antigens by human tumor-infiltrating lymphocytes. J Immunother 12:203-206, 1992
36. Storkus WJ, Zeh HJ, 3rd, Maeurer MJ, et al: Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol 151:3719-3727, 1993
37. Bakker AB, Schreurs MW, de Boer AJ, et al: Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179:1005-1009, 1994
38. Dudley ME, Wunderlich JR, Robbins PF, et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854, 2002
39. Dréno B, Nguyen JM, Khammari A, et al: Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 51:539-546, 2002
40. Moretta A, Bottino C, Mingari MC, et al: What is a natural killer cell? Nat Immunol 3:6-8, 2002